Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Radioguided Selective Neck Dissection for Staging and Treatment of Oral Cavity and Oropharyngeal Squamous Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03727594
Recruitment Status : Recruiting
First Posted : November 1, 2018
Last Update Posted : November 1, 2018
Sponsor:
Information provided by (Responsible Party):
Nicola Malagutti, University Hospital of Ferrara

Brief Summary:
The purpose of the study is to assess the role of lymphoscintigraphy as a simple and widely accessible method with a favorable cost/benefit ratio in improving oral cavity and oropharyngeal squamous cell carcinoma staging and surgical appropriateness and implementing a tailored surgical approach to cervical lymph node dissection.

Condition or disease
Oral Cavity Squamous Cell Carcinoma Oropharyngeal Squamous Cell Carcinoma

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Radioguided Selective Neck Dissection for Staging and Treatment of Oral Cavity and Oropharyngeal Squamous Cell Carcinoma
Actual Study Start Date : January 2016
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : January 2021



Primary Outcome Measures :
  1. Number of patients with atypical lymphatic drainage of oral cavity and oropharyngeal squamous cell carcinoma identified through lymphoscintigraphy [ Time Frame: 5 years ]
  2. Number of metastasis or micrometastasis in the "sentinel" lymphnodes identified through immunofluorescence analysis of pancytokeratins [ Time Frame: 5 years ]
  3. Overall survival [ Time Frame: 5 years ]
    Prognosis of radioguided neck dissection surgery compared to the standardized neck dissection traditionally performed in consideration of the site and the characteristics of the tumor and the clinical status of lymphnodes.

  4. Disease-free survival [ Time Frame: 5 years ]
    Prognosis of radioguided neck dissection surgery compared to the standardized neck dissection traditionally performed in consideration of the site and the characteristics of the tumor and the clinical status of lymphnodes.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 95 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients affected by oral cavity or oropharyngeal squamous cell carcinoma admitted to our clinic.
Criteria

Inclusion Criteria:

  • accepted informed consent
  • preoperative histological diagnosis of oral cavity or oropharyngeal squamous cell carcinoma
  • patients fit to surgery of the primitive tumor and neck dissection (according to the general health condition and the clinical tumor stage)

Exclusion Criteria:

  • rejected informed consent
  • patients not fit to surgery (according to the general health condition and the clinical tumor stage)
  • pregnant women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03727594


Contacts
Layout table for location contacts
Contact: Nicola Malagutti, MD +393339011406 nicolamalagutti@gmail.com

Locations
Layout table for location information
Italy
University Hospital of Ferrara Recruiting
Ferrara, Italy, 44124
Contact: Nicola Malagutti, MD    +393339011406    nicolamalagutti@gmail.com   
Sponsors and Collaborators
University Hospital of Ferrara

Layout table for additonal information
Responsible Party: Nicola Malagutti, Principal Investigator, University Hospital of Ferrara
ClinicalTrials.gov Identifier: NCT03727594     History of Changes
Other Study ID Numbers: 151099
First Posted: November 1, 2018    Key Record Dates
Last Update Posted: November 1, 2018
Last Verified: October 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell